Stage
Other Investors | AliveAbout Onyvax
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Loading...
Loading...
Onyvax Patents
Onyvax has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/17/2012 | 10/1/2013 | Vaccines, Immunology, Clusters of differentiation, Transcription factors, Monoclonal antibodies | Grant |
Application Date | 1/17/2012 |
|---|---|
Grant Date | 10/1/2013 |
Title | |
Related Topics | Vaccines, Immunology, Clusters of differentiation, Transcription factors, Monoclonal antibodies |
Status | Grant |
Onyvax Frequently Asked Questions (FAQ)
What is Onyvax's latest funding round?
Onyvax's latest funding round is Other Investors.
Who are the investors of Onyvax?
Investors of Onyvax include Alta Berkeley.
Who are Onyvax's competitors?
Competitors of Onyvax include ISA Pharmaceuticals, OncoMed Pharmaceuticals, Xhale, Biovertis, Activate Immunotherapy and 7 more.
Loading...
Compare Onyvax to Competitors
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.
PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.
Link Medicine is advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases.
Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Loading...